AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting ...
Today, on June 17, 2026, uniQure shared a press release with an update from their recent Type B meeting with the FDA. In ...
LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results